DEQUADIN ORAL SPRAY 0.5 %
DEQUALINIUM CHLORIDE : 0.5 % · DIN 02522616 · PHARMASCIENCE INC
Health Canada status: DORMANT
What is DEQUADIN ORAL SPRAY?
DEQUADIN ORAL SPRAY 0.5 % contains DEQUALINIUM CHLORIDE : 0.5 %. It is listed in the Health Canada Drug Product Database under DIN 02522616, held by PHARMASCIENCE INC, supplied as SOLUTION for BUCCAL administration. Health Canada currently lists it as dormant, status dated 31-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02522616 |
|---|---|
| Brand name | DEQUADIN ORAL SPRAY |
| Generic / active ingredient | DEQUALINIUM CHLORIDE : 0.5 % |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 0.5 % |
| Dosage form | SOLUTION |
| Route of administration | BUCCAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R02AA02 DEQUALINIUM |
| AHFS class | 52:04.92 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 31-Jul-2026 |
| Original market date | 2022-09-28 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code R02AA02 DEQUALINIUM. 1 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DEQUADIN | 0.25 MG | LOZENGE | PHARMASCIENCE INC | MARKETED | DIN 02100207 |
| DEQUADIN LOZENGES .25MG | .25 MG | LOZENGE | GLAXO CANADA INC | CANCELLED POST MARKET | DIN 00110566 |
| DEQUADIN ORAL PAINT | 0.5 % | SOLUTION | PHARMASCIENCE INC | DORMANT | DIN 02091453 |
| DEQUADIN ORAL PAINT .5% | 0.5 % | PAINT | GLAXO CANADA INC | CANCELLED POST MARKET | DIN 00110574 |
Who else supplies DEQUALINIUM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DEQUALINIUM appears in 2 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.